GSK receives FDA approval of Tanzeum for adults with type 2 diabetes.
GlaxoSmithKline (GSK) reported that FDA has approved Tanzeum (albiglutide) for injection, as a once-weekly treatment for adults with type 2 diabetes mellitus.
The FDA approval of albiglutide is based on the results of GSK’s Phase III Harmony program, consisting of eight trials and involving over 5000 patients, 2000 of which were treated with Tanzeum. The Harmony studies evaluated albiglutide against commonly-used classes of type 2 diabetes treatments, including insulin, metformin, glimepiride and pioglitazone, in patients at different stages of the disease, as well as those with renal impairment.
GSK expects to launch Tanzeum in the third quarter of 2014.
Source: GlaxoSmithKline
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.